Testimony on Mipomersen to the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee

View as PDF.

View press release

The Food and Drug Administration (FDA) should not approve the proposed cholesterol drug mipomersen because the study supporting approval was unethical and withheld an effective therapy from patients with a rare disease, while the drug itself causes a plethora of serious side effects.